- Home
- ICU vs TSBX Comparison
ICU vs TSBX Comparison
Compare ICU & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- TSBX
- Stock Information
- Founded
- ICU 2018
- TSBX 2015
- Country
- ICU United States
- TSBX United States
- Employees
- ICU N/A
- TSBX N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- TSBX
- Sector
- ICU Health Care
- TSBX
- Exchange
- ICU Nasdaq
- TSBX Nasdaq
- Market Cap
- ICU 9.5M
- TSBX 7.7M
- IPO Year
- ICU N/A
- TSBX 2023
- Fundamental
- Price
- ICU $0.66
- TSBX $0.35
- Analyst Decision
- ICU
- TSBX Buy
- Analyst Count
- ICU 0
- TSBX 3
- Target Price
- ICU N/A
- TSBX $4.75
- AVG Volume (30 Days)
- ICU 5.7M
- TSBX 91.5K
- Earning Date
- ICU 08-12-2025
- TSBX 08-13-2025
- Dividend Yield
- ICU N/A
- TSBX N/A
- EPS Growth
- ICU N/A
- TSBX N/A
- EPS
- ICU N/A
- TSBX N/A
- Revenue
- ICU $428,000.00
- TSBX N/A
- Revenue This Year
- ICU $754.07
- TSBX N/A
- Revenue Next Year
- ICU $100.09
- TSBX N/A
- P/E Ratio
- ICU N/A
- TSBX N/A
- Revenue Growth
- ICU N/A
- TSBX N/A
- 52 Week Low
- ICU $0.31
- TSBX $0.29
- 52 Week High
- ICU $9.09
- TSBX $2.50
- Technical
- Relative Strength Index (RSI)
- ICU 45.72
- TSBX 44.91
- Support Level
- ICU $0.53
- TSBX $0.35
- Resistance Level
- ICU $0.94
- TSBX $0.37
- Average True Range (ATR)
- ICU 0.10
- TSBX 0.01
- MACD
- ICU 0.01
- TSBX -0.00
- Stochastic Oscillator
- ICU 30.91
- TSBX 18.26
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.